» Articles » PMID: 33682890

Characteristics of Patients with Difficult-to-treat Rheumatoid Arthritis in Clinical Practice

Overview
Specialty Rheumatology
Date 2021 Mar 8
PMID 33682890
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to investigate the clinical characteristics of patients with difficult-to-treat RA (D2T RA) and the usefulness of switching to drugs with different modes of action in real-world.

Methods: We reviewed all consecutive patients with RA treated at Keio University Hospital between 2016 and 2017 with a definition of D2T RA. We analysed clinical characteristics and evaluated the usefulness of changing drugs according to mode of action.

Results: Among 1709 patients with RA, 173 (10.1%) were D2T RA. The reason for the D2T RA was multi-drug resistance in 59 patients (34.1%), comorbidity in 17 (9.8%), and socio-economic reasons in 97 (56.1%). The multi-drug-resistance group had significantly higher tender joint count and evaluator global assessment than the other groups, despite receiving the most intensive treatment. The comorbidity group showed a significantly older age and higher rheumatic disease comorbidity index. Although changing the drug to another with a different mode of action was useful, the proportion of patients who achieved remission or low disease activity decreased as the number of switches increased.

Conclusion: Of the patients with RA, 10.1% were still difficult to treat in clinical practice, despite intensive treatment. Their characteristics were distinct by the reasons of D2T RA, which suggests the need for a personalized approach to D2T RA.

Citing Articles

The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study.

Berthelot W, Sirois C, Julien A, Amiable N, Bessette L, Desaulniers P Rheumatol Int. 2025; 45(3):44.

PMID: 39921727 DOI: 10.1007/s00296-025-05804-8.


Long-term outcome of a treat-to-target strategy in late-onset rheumatoid arthritis with chronic lung disease: 5-year results of a prospective observational study.

Nomura M, Sugihara T, Baba H, Hosoya T, Kamiya M, Ishizaki T Arthritis Res Ther. 2025; 27(1):22.

PMID: 39901281 PMC: 11789366. DOI: 10.1186/s13075-025-03491-1.


Upregulation of interferon-γ response genes in monocytes and T cells identified by single-cell transcriptomics in patients with anti-citrullinated peptide antibody-positive early rheumatoid arthritis.

Hong B, You S, Kim J, Kim M, Lee N, Lee K Front Immunol. 2025; 15:1439082.

PMID: 39877346 PMC: 11772891. DOI: 10.3389/fimmu.2024.1439082.


Unmet Needs and Current Challenges of Rheumatoid Arthritis: Difficult-to-Treat Rheumatoid Arthritis and Late-Onset Rheumatoid Arthritis.

Takanashi S, Kaneko Y J Clin Med. 2025; 13(24).

PMID: 39768516 PMC: 11679914. DOI: 10.3390/jcm13247594.


Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat.

DOnofrio B, De Stefano L, Bozzalla Cassione E, Morandi V, Cuzzocrea F, Sakellariou G Arthritis Res Ther. 2024; 26(1):192.

PMID: 39516929 PMC: 11545058. DOI: 10.1186/s13075-024-03431-5.